ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial Of CoFactor(R)

ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company’s folate-based biomodulator of 5-FU (5 fluorouracil), for the treatment of first-line metastatic colorectal cancer. The primary endpoint of the study was progression-free survival, which is expected to mature and be reported by the Company along with safety data later this year.

More: continued here

Filed under: Clinical Trials on July 4th, 2008